| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
33,976 |
29,700 |
$1.00M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
12,540 |
11,162 |
$492K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
9,364 |
8,345 |
$328K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
14,634 |
13,410 |
$169K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
9,352 |
4,453 |
$110K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,229 |
1,121 |
$58K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
652 |
604 |
$49K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
691 |
639 |
$48K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
4,757 |
2,146 |
$45K |
| 87428 |
|
882 |
643 |
$41K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,611 |
2,515 |
$32K |
| 99091 |
|
188 |
186 |
$29K |
| 99000 |
|
3,194 |
2,885 |
$23K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
236 |
219 |
$16K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,216 |
1,075 |
$12K |
| 87807 |
|
827 |
737 |
$8K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
218 |
208 |
$8K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
803 |
680 |
$6K |
| 90461 |
|
1,161 |
862 |
$5K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
223 |
215 |
$4K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
49 |
47 |
$4K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
110 |
109 |
$3K |
| 81002 |
|
1,018 |
958 |
$2K |
| 90756 |
|
71 |
64 |
$1K |
| 81025 |
|
114 |
112 |
$746.54 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
113 |
111 |
$638.60 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
828 |
739 |
$545.92 |
| 99215 |
Prolong outpt/office vis |
14 |
14 |
$435.89 |
| 90674 |
|
73 |
64 |
$412.64 |
| 92551 |
|
154 |
143 |
$307.69 |
| 80305 |
|
42 |
39 |
$290.57 |
| 90734 |
|
146 |
139 |
$288.98 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
141 |
119 |
$192.08 |
| 90661 |
|
13 |
13 |
$78.30 |
| 90696 |
|
26 |
24 |
$52.46 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
13 |
13 |
$51.31 |
| 99304 |
|
52 |
51 |
$43.95 |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
114 |
91 |
$31.71 |
| 90715 |
|
136 |
130 |
$31.51 |
| 36415 |
Collection of venous blood by venipuncture |
226 |
218 |
$8.57 |
| 90619 |
|
74 |
72 |
$0.62 |
| 1036F |
|
12,590 |
11,072 |
$0.00 |
| 90688 |
|
12 |
12 |
$0.00 |
| 96127 |
|
29 |
23 |
$0.00 |
| 90716 |
|
13 |
13 |
$0.00 |
| 1160F |
|
16,568 |
14,638 |
$0.00 |
| 1159F |
|
16,554 |
14,626 |
$0.00 |
| 99173 |
|
528 |
477 |
$0.00 |
| 90670 |
|
12 |
12 |
$0.00 |
| 99051 |
|
91 |
90 |
$0.00 |
| 90633 |
|
18 |
18 |
$0.00 |
| 90710 |
|
32 |
30 |
$0.00 |
| 90707 |
|
13 |
13 |
$0.00 |